SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Teva Unit Buys Rights to BXCL501 From BioXcel Therapeutics

Valid market news retained in the public archive without immediate LiveCast distribution.

TEVA

Related stories